Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
Key Highlights
- ➤EQ504 preclinical data show coordinated epithelial and immune effects in intestinal co-culture
- ➤EQ504 preserved barrier integrity while suppressing inflammatory cytokine production
- ➤Equillium will present EQ504 findings October 6 at La Jolla Immunology Conference
- ➤EQ504 is designed for potential ulcerative colitis treatment via enteric-coated delivery
Expert Statements
Stephen Connelly, Chief Scientific Officer of Equillium
“These data provide additional insight into the multi-modal activity of EQ504, demonstrating coordinated effects across epithelial and immune compartments that preserve barrier integrity while resolving inflammation.”
Stephen Connelly, Chief Scientific Officer of Equillium
“We believe these complementary effects are particularly relevant to ulcerative colitis, where both reducing inflammation and improving mucosal healing are important to achieving meaningful outcomes for patients.”
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50(th) (link) Anniversary La Jolla Immunology Conference, taking place October 6-8, 2026 in La Jolla, California.
“These data provide additional insight into the multi-modal activity of EQ504, demonstrating coordinated effects across epithelial and immune compartments that preserve barrier integrity while resolving inflammation,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “We believe these complementary effects are particularly relevant to ulcerative colitis, where both reducing inflammation and improving mucosal healing are important to achieving meaningful outcomes for patients.”
Get started
Create a free account to read the full story.